Articles tagged "HLA antibodies"

2016 American Transplant Congress
Significant Association of Vitamin-D Receptor (VDR) Gene Polymorphism and Incidence of De Novo DSA in Renal Transplantation.
L. Das, K. Ide, Y. Tanaka, N. Tanimine, S. Verma, H. Ohdan.
Department of Gastroenrological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Objective-Renal Transplantation (RT) is the optimal choice forend stage renal disease. Despite all advances in the development ofeffective immunosuppressive regimens in renal transplantation one of…
2016 American Transplant Congress
Predicting Emergence of Anti-HLA Class I and II Antibodies by Time Dependent Phenomapping in Heart Transplant Patients.
M. Bakir, N. Jackson, E. Chang, D. Henriquez-Ticas, C.-H. Tseng, T. Khuu, J. Zhang, E. Reed, M. Deng, M. Cadeiras.
Cardiology, University of California-Los Angeles, Los Angeles, CA.
Purpose: The presence of circulating HLA antibodies which is termed allosensitization among heart transplant (HTx) candidates are associated with poorer posttransplant outcomes including increased morbidity…
2016 American Transplant Congress
Predicting the Ability of Anti-HLA Antibodies to Activate Complement.
D. Bekbolsynov, C. Baum, B. Mierzejewska, A. Malebari, M. Rees, S. Stepkowski.
University of Toledo, Toledo.
Purpose: The single antigen bead (SAB) assay measures binding of antibodies (Abs) to HLA in units of mean florescence intensity (MFI). Two assays measure the…
2016 American Transplant Congress
TNT009 and Its Parental Mouse Monoclonal Antibody TNT003 Target Complement Component C1s and Effectively Block Alloantibody-Induced Classical Complement Pathway Activation – The Preclinical Experience.
M. Wahrmann,¹ J. Mühlbacher,¹ H. Regele,¹ F. Eskandary,¹ J. Gilbert,² S. Panicker,² G. Böhmig.¹
¹VIETAC Laboratories, Medical University of Vienna, Vienna, Austria; ²True North Therapeutics, Inc., South San Francisco, CA.
Introduction. Considering the key role of the classical complement pathway as a trigger of inflammation and injury in antibody-mediated rejection (ABMR), targeted classical pathway inhibition…
2016 American Transplant Congress
Differential Regulation of the Microvascular Endothelial Cell Mediated Allogeneic CD4+ T Cell Response by Anti-HLA-DR and -DQ Alloantibodies in an Inflammatory Context.
N. Mooney,^1,2 A. Cross,^1,2 J. Lion,^1,2 A. Haziot,^1,2 D. Glotz.^1,2,3
¹INSERM UMRS 1160, Institut Universitaire d'Hématologie, Paris, France; ²Université-Paris-Diderot, Sorbonne Paris Cité, Paris, France; ³Service de Néphrologie et Transplantation, Hôpital Saint Louis, Paris, France.
This study examines the basic mechanisms by which high levels of circulating HLA class II donor-specific-antibodies can contribute to microvasculature damage in chronic antibody mediated…
2016 American Transplant Congress
Increased Access to Transplantation of Highly Sensitized Patients Facilitated by the New Kidney Allocation System.
A. Colovai, M. Ajaimy, C. Savchik, S. Chan, P. Masiakos, J. Rocca, E. Akalin.
Abdominal Transplant, Montefiore Medical Center, Bronx, NY.
The purpose of our study was to evaluate the impact of the new kidney allocation system (KAS 2014) on the access to transplantation of HLA…
2016 American Transplant Congress
Impact of Donor Specific Antibodies on Cardiac Allograft Vasculopathy.
A. Vu,¹ A. Althouse,² A. Zeevi,³ J. Teuteberg,² M. Shullo.²
¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Pathology Department, University of Pittsburgh, Pittsburgh, PA.
Purpose: Cardiac allograft vasculopathy (CAV) is a significant complication after cardiac transplantation (CTX). The presence of donor specific antibodies (DSA) has been associated with an…
2016 American Transplant Congress
The Phenotypic Diversity of Late Silent Antibody-Mediated Rejection.
F. Eskandary,^1,2 J. Reeve,^1,3 H. Regele,⁴ L. Hidalgo,^1,3 D. Yoo,¹ N. Kozakowski,⁴ K. Famulski,¹ G. Böhmig,² P. Halloran.^1,5
¹Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada; ²Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria; ³Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ⁴Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria; ⁵Department of Medicine, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, AB, Canada.
Study purpose: ABMR is a driving force of long-term allograft loss in organ transplantation. The present study was designed to characterize the phenotypic diversity of…
2016 American Transplant Congress
Reduced Incidence and Level of De Novo Donor-Specific Antibodies in Belatacept-Treated vs. Cyclosporine-Treated Patients: Final Results from BENEFIT.
R. Bray,¹ H. Gebel,¹ R. Townsend,² M. Polinsky,² L. Yang,² U. Meier-Kriesche,² C. Larsen.¹
¹Emory University, Atlanta, GA; ²Bristol-Myers Squibb, Lawrenceville, NJ.
Background: The presence of donor-specific antibodies (DSA) has been associated with an increased risk of antibody-mediated rejection and graft failure. Mean fluorescence intensity (MFI) is…
2016 American Transplant Congress
Mothers Are Often Sensitized and Sensitive: Antibody Mediated Rejection in Child to Mother Living Donor Liver Transplantation.
B. Movahedi,¹ N. Yu,² P. Martins,¹ A. Ahearn,¹ J. Stoff,¹ A. Bozorgzadeh.¹
¹Division of Organ Transplantation, UMass Memorial Medical Center, Worcester, MA; ²Clinical Pathology, Histocompatibility Laboratory, UMass Memorial Medical Center, Worcester, MA.
Background: Partial graft is especially more vulnerable to deleterious effects of donor specific HLA antibodies (DSA). Living liver donors and recipients are often family members.…